Table 3 Comparisons of differentially expressed phosphorylated peptides related to metabolic pathways treated with PZH and sorafenib from TMT phosphoproteomics and PRM verification.
From: Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma
Uniprot | KEGG pathways | Protein description Peptide name | Phosphorylation fold change | |||||
|---|---|---|---|---|---|---|---|---|
PZH versus control | Sora versus control | PZH versus sora | ||||||
TMT Phospho proteomics | PRM | TMT Phospho proteomics | PRM | TMT Phospho proteomics | PRM | |||
O70250 | Glucagon signaling pathway Glycolysis/gluconeogenesis | Phosphoglycerate mutase 2 (PGAM2) | \ | \ | \ | \ | \ | \ |
Peptide (residues 129–139): HGESLWNQENR | 0.68# | 0.63** | 0.88* | 0.79* | 0.64** | 0.80# | ||
Peptide (residues 12–20): HNYYTSISK | 0.48* | 0.41** | 1.21 | 0.64** | 0.55** | 0.63* | ||
P06151 | L-lactate dehydrogenase A chain (LDHA) | \ | \ | \ | \ | \ | \ | |
Peptide (residues 233–243): QVVDSAYEVIK | 0.66 | 0.45** | 1.23 | 0.72* | 0.53** | 0.62** | ||
P47857 | Glycolysis/gluconeogenesis HIF-1 signaling pathway Fructose and mannose metabolism | ATP dependent 6-phosphofructokinase (PFK1) | \ | \ | \ | \ | \ | \ |
Peptide (residues 657–673): NVLGHMQQGGSPTPFDR | 0.89 | 0.25** | 1.12 | 0.23** | 0.79* | 1.09 | ||
P05064 | Fructose bisphosphate aldolase A (ALDOA) | \ | \ | \ | \ | \ | \ | |
Peptide (residues 44–56): LQSIGTENTEENR | 0.84 | 0.34** | 1.18* | 0.54* | 0.71** | 0.53* | ||
Peptide (residues 29–42): GILAADESTGSIAK | 0.57 | 0.49** | 1.50* | 0.64** | 0.45** | 0.76* | ||
Q9QXG4 | Glycolysis/gluconeogenesis Pyruvate, propanoate metabolism | Acetyl-coenzyme A synthetase (ACSS2) | \ | \ | \ | \ | \ | \ |
Peptide (residues 28–36): GWSPPPEVR | 0.89 | 1.08 | 1.32** | 1.26* | 0.54* | 0.86 | ||
P41216 | PPAR signaling pathway Fatty acid biosynthesis/degradation | Long chain fatty acid CoA ligase (ACSL1) | \ | \ | \ | \ | \ | \ |
Peptide (residues 421–428): IQSSLGGK | 0.71# | 0.25** | 1.34* | 0.68 | 0.53** | 0.37** | ||